A detailed history of Los Angeles Capital Management LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 31,197 shares of ALT stock, worth $190,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,197
Previous 66,537 53.11%
Holding current value
$190,613
Previous $408,000 45.1%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 04, 2025

SELL
$6.02 - $9.85 $212,746 - $348,099
-35,340 Reduced 53.11%
31,197 $224,000
Q3 2024

Nov 04, 2024

SELL
$5.5 - $8.1 $203,868 - $300,242
-37,067 Reduced 35.78%
66,537 $408,000
Q2 2024

Aug 05, 2024

BUY
$5.91 - $10.23 $612,299 - $1.06 Million
103,604 New
103,604 $688,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $300M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.